שווי מתואם לחוב ומזומנים Alterity Therapeutics (ATHE)

The quotes below illustrate the price action of Alterity Therapeutics (ATHE), where the Enterprise Value is 15.73. Alterity Therapeutics focuses on developing innovative therapies for Parkinson's disease to ensure long-term patent protection. The business minimizes regulatory risks through a broad portfolio of small molecule research. Meanwhile, the company's success critically depends on FDA decisions regarding ATH434, which remains the sole hope for patients with multiple system atrophy.

Enterprise Value represents the final buyout price of a business, combining market capitalization and net debt. By analyzing the total value inclusive of debt, an investor sees the actual cost of acquiring the asset. The formula adjusts the equity value for the volume of borrowed funds and available cash. For the biotech company Alterity Therapeutics (ATHE), this is critical when assessing the value of neurotherapy development. Effective liquidity management directly impacts the dynamics of this metric.